Evotec
Florence Eustache has had extensive work experience at Evotec. Florence started their career as a Senior Scientist in 2003 and held the position until 2009. Florence then progressed to various roles in Business Development, including Business Development Executive from 2013 to 2016, Business Development Manager for Europe from 2016 to 2018, and Director of Business Development from 2018 to 2021. Florence was then promoted to Senior Director of Business Development from 2021 to 2022 before assuming their current role as Vice President of Business Development since May 2022.
Florence Eustache obtained a PhD in Organic Chemistry from Pierre and Marie Curie University, where they studied from 1999 to 2002. Prior to that, they pursued their studies at ESPCI - Ecole Superieur de Physique et Chimie Industrielles and obtained an Ingenieur degree in Chemistry from 1997 to 1999. Details about any education before 1997 or after 2002 are not provided. Florence also attended Lycee F. Chopin, but specific details about the degree or field of study are not available.
This person is not in the org chart
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.